Journey Medical Corp (DERM) Stock Forecast & Price Target
Journey Medical Corp · NASDAQ
$7.96+0.10 (+1.21%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Journey Medical Corp, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $13.00 to $15.00, so the covering firms are broadly aligned. The average target of $14.00 sits 76% above the current $7.96. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.04 next quarter toward $0.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Journey Medical Corp.
As of Sep, 2 of 2 firms rate DERM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DERM EPS & revenue forecast
EPS · NEXT QUARTER
$0.04
Range $0.02 – $0.08 · 4 analysts · -194% YoY
Next period, 4 analysts expect Journey Medical Corp to earn $0.04 a share (range $0.02 – $0.08), versus $-0.04 a year earlier. Full-year consensus is $-0.04, growing to $0.68 the year after.
REVENUE · NEXT QUARTER
$25.0M
Range $21.9M – $27.2M · 4 analysts · +56% YoY
Revenue is expected to reach $25.0M (range $21.9M – $27.2M), +55.6% year-over-year. Full-year consensus is $81.4M, rising to $130.4M next year.
Top analysts covering Journey Medical Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DERM.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$15.00+88.6% to target
Overall win rate
50%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$13.00+63.4% to target
Overall win rate
42%
+ Follow
#3
TF
Thomas Flaten
Lake Street · Rank #238
Buy
$13.00+63.4% to target
Overall win rate
40%
+ Follow
#4
KP
Kalpit Patel
B. Riley Securities
Buy
$12.00+50.8% to target
Coverage
—
+ Follow
DERM stock forecast FAQ
What is DERM's average 12-month price target?+
The 2 analysts with a live target average $14.00 for Journey Medical Corp over the next 12 months, ranging from a $15.00 high to a $13.00 low.
Is DERM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DERM?+
The Street-high target is $15.00 (B. Riley Securities), and the Street-low is $13.00 (HC Wainwright & Co.). The average of all 2 active targets is $14.00.
How many Wall Street analysts cover DERM?+
2 analysts have an active rating on Journey Medical Corp, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering DERM?+
Among analysts who currently cover DERM, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $15.00 target.
What is Journey Medical Corp's projected EPS for next quarter?+
The consensus estimate is $0.04 per share (range $0.02 – $0.08) across 4 analysts. Full-year EPS is projected at $-0.04, rising to $0.68 the following year.
How much revenue is Journey Medical Corp expected to report next quarter?+
Consensus revenue is $25.0M (range $21.9M – $27.2M). Full-year revenue is projected at $81.4M, growing to $130.4M next year.
Have analysts been upgrading or downgrading DERM lately?+
As of Sep, 2 of 2 firms rate DERM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DERM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
